Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies

Authors:

Abstract
This Viewpoint discusses the risk-benefit assessments in psychedelic and 3,4-methylenedioxymethamphetamine (MDMA)–assisted therapies.